Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966199 | 0.79 | EPHX1 (0.37) | MEN1ALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL962061 | 0.78 | THRB (0.40) | MEN1ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL963002 | 0.71 | — | — | |
| SCHEMBL16440072 | 0.69 | SIGMAR1 (0.54) | MEN1HTTKMT2ASIGMAR1TMEM97 | |
| SCHEMBL16440071 | 0.69 | SIGMAR1 (0.54) | MEN1HTTKMT2ASIGMAR1TMEM97 | |
| SCHEMBL5353568 | 0.69 | HSD11B1 (0.56) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL27008249 | 0.68 | SLC6A2 (0.64) | ALDH1A1TMEM97 | |
| SCHEMBL965468 | 0.67 | SIGMAR1 (0.49) | MEN1ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL16449452 | 0.67 | DRD2 (0.59) | MEN1ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL5366293 | 0.67 | HTT (0.67) | MEN1HTTKMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | MEN1 3268/4885ALDH1A1 4653/4885LMNA 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.